Adalimumab is a monoclonal antibody drug that can be used to treat rheumatoid arthritis, psoriasis, ankylosing spondylitis and other diseases.
Adalimumab is a monoclonal antibody drug that can specifically bind to tumor necrosis factor α and block its interaction with the tumor necrosis factor receptor, thus playing an anti-tumor necrosis factor α role, and is currently commonly used in the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease and other diseases.
Adalimumab common adverse drug reactions include infection, injection site redness, swelling and pain, headache, musculoskeletal pain, etc. Patients who are allergic to the components of the drug, patients with active tuberculosis or other infections, and patients with moderate or severe heart failure are prohibited from using the drug, in addition to mild heart failure, patients under 2 years of age, and patients with malignant tumors need to be cautious about the use of the drug.
Adalimumab should be used under the guidance of a physician, and it is recommended that patients who need to use adalimumab treatment go to the rheumatology and immunology department of a regular hospital or other relevant departments for detailed consultation.